BPG is committed to discovery and dissemination of knowledge
Featured Articles
11/14/2014 8:31:00 AM | Browse: 860 | Download: 1422
 |
Received |
|
2013-12-31 08:48 |
|
Peer-Review Started |
|
2013-12-31 09:30 |
 |
First Decision by Editorial Office Director |
|
|
|
Return for Revision |
|
2014-02-24 10:25 |
|
Revised |
|
2014-03-28 20:26 |
|
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2014-09-17 14:03 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2014-09-17 14:32 |
|
Articles in Press |
|
2014-09-17 14:32 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2014-10-31 10:14 |
|
Publish the Manuscript Online |
|
2014-11-13 16:59 |
| Category |
Dermatology |
| Manuscript Type |
Review |
| Article Title |
Psoriasis: Biologic treatment and liver disease
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Eva Vilarrasa and Luis Puig |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Eva Vilarrasa, MD, Physician Staff, Psoriasis Unit, Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, C/ Sant Antoni Maria Claret 167, 08025 Barcelona,
Spain. evilarrasa@santpau.cat
|
| Key Words |
Psoriasis; Liver disease; Biologic; Anti-tumor necrosis factor-alpha; Ustekinumab; Chronic hepatitis C; Chronic hepatitis B; Alcoholic liver disease; Non-alcoholic fatty liver disease |
| Core Tip |
Eva Vilarrasa, MD, Physician Staff, Psoriasis Unit, Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, C/ Sant Antoni Maria Claret 167, 08025 Barcelona,
Spain. evilarrasa@santpau.cat
|
| Publish Date |
2014-11-13 16:59 |
| Citation |
Vilarrasa E, Puig L. Psoriasis: Biologic treatment and liver disease. World J Dermatol 2014; 3(4): 76-85 |
| URL |
http://www.wjgnet.com/2218-6190/full/v3/i4/76.htm |
| DOI |
http://dx.doi.org/10.5314/wjd.v3.i4.76 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
